Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Copenhagen Stock Exchange  >  Novo Nordisk A/S    NOVO.B   DK0060534915

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Develops, manufactures, markets and distributes pharmaceutical products

Novo Nordisk AS engages in the research, development, manufacture, and marketing of pharmaceutical products.

It operates through the Diabetes and Obesity Care; and Biopharmaceuticals segments.

The Diabetes and Obesity Care segment covers insulins, glucagon-like-peptide 1, other protein-related products, oral anti-diabetic drugs and obesity.

The Biopharmaceuticals segment handles the research, development, manufacture, and distribution of products within the areas of haemophilia, growth hormone, hormone replacement, inflammation and other therapy areas.

The company was founded in 1923 by August Krogh, Marie Krogh, Hans Christian Hagedorn, August Kongsted, Harald Pedersen, and Thorvald Pedersen and is headquartered in Bagsværd, Denmark.

Number of employees : 40 638 persons.
Sales per Businesses
20142015Delta
DKK (in Million)%DKK (in Million)%
Diabetes & Obesity Care69,98078.8%85,59079.3% +22.31%
Biopharmaceuticals18,82621.2%22,33720.7% +18.65%
Sales per Regions
20142015Delta
DKK (in Million)%DKK (in Million)%
North America43,12348.6%56,85752.7% +31.85%
Europe20,15022.7%20,79819.3% +3.22%
International12,54014.1%14,96613.9% +19.35%
China8,0889.1%9,8719.1% +22.05%
Japan & Korea4,9055.5%5,4355% +10.81%
Managers
NameAgeSinceTitle
Lars Rebien Sørensen621982President & Chief Executive Officer
Göran Ando672005Chairman
Jesper Brandgaard, MBA531999Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen, PhD561991Chief Science Officer & Executive Vice President
Alan C. Moses, MD-2008Global Chief Medical Officer
Anne Marie Handrup Kverneland601981Director
Stig Strøbæk521992Director
Bruno Francois Jules Angelici, MBA692011Independent Non-Executive Director
Thomas Paul Koestler, PhD652011Independent Director
Elizabeth Anne Hewitt602012Independent Non-Executive Director
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 2,012,564,000 1,796,581,297 89.3% 52,168,703 2.6% 70.5%
Share B 10 537,436,000 0 0.0% 0 0.0%
Shareholders
NameEquities%
Novo Nordisk Fonden 163,814,000 8.14%
Capital Research & Management Co. (World Investors) 161,050,176 8.00%
Norges Bank Investment Management 36,416,979 1.81%
The Vanguard Group, Inc. 36,114,310 1.79%
Northern Cross LLC 27,779,340 1.38%
Carmignac Gestion SA 26,104,052 1.30%
BlackRock Investment Management (UK) Ltd. 22,141,292 1.10%
Alecta Pension Insurance Mutual 20,908,000 1.04%
BlackRock Fund Advisors 17,027,673 0.85%
Jupiter Asset Management Ltd. 12,581,279 0.63%
Holdings
NameEquities%Valuation
Novo Nordisk A/S (NOVO.B) 10,357,6450.51%562,720,081 USD
Nnit A/S (NNIT) 6,375,00025.5%165,762,941 USD
Innate Pharma (IPH) 5,422,70810.1%75,203,850 USD
Pieris Pharmaceuticals Inc (PIRS) 2,051,8025.15%3,898,424 USD
Sector
Healthcare
Pharmaceuticals & Medical Research
 Pharmaceuticals
  Pharmaceuticals
   Pharmaceuticals - NEC
Advertisement
Sector Pharmaceuticals
Growth (Revenue) Profitability
JOHNSON & JOHNSON
ROCHE HOLDING LTD..
NOVARTIS AG
PFIZER INC.
MERCK & CO., INC.
BRISTOL-MYERS SQU..
NOVO NORDISK A/S
SANOFI
GLAXOSMITHKLINE P..
BAYER AG
ALLERGAN PLC
ELI LILLY AND CO
ASTRAZENECA PLC
ABBOTT LABORATORI..
TEVA PHARMACEUTIC..
-
TAKEDA PHARMACEUT..
SHIRE PLC
ASTELLAS PHARMA I..
MYLAN NV
CHUGAI PHARMACEUT..
Sector Pharmaceuticals
Novo Nordisk A/S : Connections
EUSA Pharma (Europe) Ltd.
Arisaph Pharmaceuticals, Inc.
RAND Health
The International Centre for Missing & Exploited Children
Essex Woodlands Health Ventures UK Ltd.
Steno Diabetes Center A/S
Novo A/S
Novo Nordisk Fonden
Archimedes Pharma UK Ltd.
Danmarks Nationalbank
Novo Nordisk Region Japan & Korea A/S
ImmusanT, Inc.
Novo Nordisk Region Europe A/S
Bio*One Capital Pte Ltd.
Novo Nordisk Region International Operations A/S
University of Copenhagen
Novo Nordisk Gsc Holding A/S
New England Healthcare Institute
Essex Bidco Ltd.
SWMF Life Science Venture Fund LP
Symphogen A/S
Bertelsmann Management SE
Carlsberg Breweries A/S
Melinta Therapeutics, Inc.
Novo Nordisk Region North America Ii A/S
Vatera Holdings LLC
Novo Nordisk Holding Ltd.
Pearl Therapeutics, Inc.
Novo Nordisk China Pharmaceuticals Co. Ltd.
Edgemont Pharmaceuticals LLC
Novo Nordisk Pharmaceuticals A/S
Novo Nordisk Invest 2 A/S
Novo Nordisk Region China A/S
Silverwood Property Ltd.
Company contact information
Novo Nordisk A/S
Novo Allé
Bagsværd, Capital Region 2880

Phone : +45.44.44.88.88
Fax : +45.44.49.05.55
Web : www.novonordisk.com
© 2016 People , Fundamentals and Ownership